Disclosing Alzheimer's Disease Diagnosis to Patients

Benefits of Disclosure

The American Academy of Neurology recommends that clinicians honestly and compassionately inform patients of their Alzheimer's disease diagnosis using a structured process, as this promotes patient autonomy and enables proper care planning 1, 2, 3
Diagnostic disclosure enables patients to participate in care planning, make informed decisions about their future, and access appropriate treatments 4
Early disclosure allows patients to make important legal, financial, and care decisions while they still maintain decision-making capacity 5
Knowledge of AD pathology helps patients understand and classify their memory disorders, reducing uncertainty 6

The American Geriatrics Society recommends evaluating the patient's capacity to understand and appreciate the information before disclosure 1, 2
Consider the patient's psychological profile and coping mechanisms before disclosure 6
Assess pre-existing knowledge about Alzheimer's disease before disclosure 6
Use a structured, standardized approach to communicate the diagnosis, including both the patient and care partner(s) in the disclosure process 1, 3, 7
Communicate honestly and compassionately about the name, characteristics, and severity of the cognitive-behavioral syndrome, the disease(s) likely causing the syndrome, the stage of the disease, what can reasonably be expected in the future, treatment options and expectations, and potential safety concerns 1, 3

Provide written summaries of the diagnosis and treatment information 8
Offer referrals to supportive and social services 8
Schedule follow-up appointments to address emerging questions and provide emotional support 8, 9
Provide psychoeducational information about secondary preventive measures and lifestyle modifications 4
Offer psychosocial support to both the patient and caregiver 9, 10

Tailor the disclosure process to the individual patient's needs, capacity, and circumstances 1, 2
Different methods may be needed to disclose the diagnosis to the patient versus the care partner, based on the patient's capacity 1, 7
The timing and content of information should be guided by the patient's capacity and the clinician's judgment about the likely impact 1, 2

Studies show that disclosure of Alzheimer's disease diagnosis is generally not associated with significant psychological harm 8
Research participants with subjective cognitive decline who received disclosure of pathological amyloid PET findings did not experience increased anxiety or depression in short-term (6 weeks) or long-term (52 weeks) follow-up 8, 10
Care partners of persons with MCI or dementia did not show significant changes in depressive symptoms, subjective burden, or loneliness after disclosure of elevated amyloid status 8, 10

Withholding diagnosis due to fear of causing psychological harm (research shows this is generally unfounded) 8
Failing to provide adequate post-disclosure support and follow-up 8, 9
Not including care partners in the disclosure process when appropriate 1, 3
Neglecting to assess the patient's understanding of the disclosed information 1, 2